Estera® Phase II Women's Transitions Formula

Six-dimension breakdown

Why this scored 53/100

Estera Phase II is Nu Skin's perimenopause-positioned formula in the three-phase Estera women's line, 60 softgels. The perimenopause segment typically uses black cohosh (Actaea racemosa, EMA HMPC monograph for hot flashes), soy isoflavones, chasteberry, and sometimes DIM (diindolylmethane) for estrogen metabolism support. The product copy specifically mentions working with the liver to promote 'a healthy ratio of estrogen metabolites' — this is a reference to the 2-OH:16α-OH estrone ratio, which DIM and I3C (indole-3-carbinol) do modulate in published human studies (Michnovicz 1997, Dalessandri 2004). Individual ingredient evidence: black cohosh has mixed evidence — the 2013 Cochrane review found insufficient evidence for hot flash reduction but the EMA HMPC monograph still supports traditional use; soy isoflavones have Grade B for modest vasomotor symptom reduction; DIM has Grade B evidence for shifting estrogen metabolite ratios but Grade C for clinical outcomes. Same 'Phase' sequenced-protocol overreach as Phase I. Standard Nu Skin MLM caveats. Rejected primarily on the sequenced-protocol framing and the transparency gap.

Evidence & sources

The Vyvata score's Evidence dimension measures the quality of published RCT support for a product's active ingredients at the label dose. Our source hierarchy: double-blind RCTs in MEDLINE-indexed journals > single-blind RCTs > open-label trials > observational studies > mechanism papers > N=1 case studies (anecdotes). Predatory journals and manufacturer-authored studies without independent replication are weighted down.

Product-specific evidence citations for this item are embedded in the analysis text on the "Analysis" tab. For the full framework and evidence hierarchy, see the methodology page.

How to read the Evidence dimension

• 80–100: Multiple double-blind RCTs in indexed journals directly testing this product OR the exact ingredients at the exact dose.
• 60–79: Single double-blind RCT + supporting ingredient literature at the studied dose.
• 40–59: Open-label trials + ingredient literature; no product-specific double-blind evidence.
• 20–39: Ingredient literature only; no product-specific trials or trials in predatory venues.
• 0–19: No credible evidence base or unverifiable claims.

FAQ data has not been generated for this product yet. See the site FAQ for general questions.

Customer reviews

All the data we have on this product

Every VSF-related metafield surfaced verbatim. Nothing hidden. If you spot data that looks wrong, let us know.

VSF score

53 / 100

Tier

Rejected

Category

Supplements

Subcategory

womens health

Last scored

August 29, 2026

Third-party certifications

None on record at time of scoring

Vendor

Leaders Beauty & Wellness

Tags

Leaders Beauty & Wellness, Shopify Collective

Every score is set from the published rubric, audit-logged, and rescored whenever new evidence emerges (published trials, updated labels, third-party testing releases). Every vendor is scored on the same criteria — no pay-to-play. See our editorial-independence disclosure for the full policy, including brands with an editorial relationship to this site.